Mode
Text Size
Log in / Sign up
Phase 4 Completed N=230 Treatment

RNS® System LTT Study

Source: ClinicalTrials.gov NCT00572195 ↗
Enrolled (actual)
230
Serious AEs
77.0%
Results posted
Jun 2019
Primary outcomePrimary: Number of Participants With Serious Adverse Events (SAE) — 177 Participants
◆ Published Evidence
Highly cited
643citations · ~58 / year
Long-term treatment with responsive brain stimulation in adults with refractory partial seizures.
Neurology · 2015 · Open access · High-confidence link

Summary

The RNS® System LTT study is designed to assess the ongoing safety and to evaluate the long-term efficacy of the RNS® System as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures that are refractory to two or more antiepileptic medications. Candidates will continue to receive their epilepsy medications while participating in the trial.

Linked Publications (3)

  • Long-term treatment with responsive brain stimulation in adults with refractory partial seizures.
    Neurology · 2015 · 643 citations · Open access · High-confidence link
  • Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy.
    Neurology · 2020 · 489 citations · Open access · Likely link
  • Chronic unlimited recording electrocorticography-guided resective epilepsy surgery: technology-enabled enhanced fidelity in seizure focus localization with improved surgical efficacy.
    Journal of neurosurgery · 2014 · 78 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Serious Adverse Events (SAE)
177
PRIMARY
Percentage Change From Baseline in Seizure Frequency
-31.5; -46.2; -46.7; -50.3; -58.3; -61.1 <0.05 sig
SECONDARY
Responder Rate
33.2; 46.7; 47.6; 50.2; 56.4; 57.8
SECONDARY
QOLIE (Quality of Life in Epilepsy)
46.1; 49.2; 49.3; 48.8; 48.1; 48.4 <0.0001 sig
SECONDARY
Adverse Event Rate
228

Eligibility Criteria

Inclusion Criteria

  • Subject has completed either the RNS® System Pivotal or Feasibility study
  • Subject has an implanted RNS® System
  • Subject has elected to continue to receive responsive neurostimulation therapy after completion of the RNS® System Pivotal or Feasibility study
  • Subject is able to attend scheduled appointments for the RNS® System LTT study

Exclusion Criteria

  • Subject has active psychiatric or medical illness that makes it inadvisable for the subject to continue to receive responsive neurostimulation therapy with the RNS® System
  • Subject has been diagnosed with psychogenic or non-epileptic seizures, or primarily generalized seizures during the RNS® System Pivotal or Feasibility study
  • Subject has been noncompliant with scheduled appointments during the RNS® System Pivotal or Feasibility study
  • Subject has been noncompliant with maintaining seizure diaries during the RNS® System Pivotal or Feasibility study
  • Informed consent cannot be obtained from subject or caregiver
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00572195) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search